Has Bryan Manhardt received payments from drug or device companies?

Yes. Drug and device makers reported $4,147 in general payments to Bryan Manhardt across 212 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bryan Manhardt did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bryan Manhardt come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bryan Manhardt

Medical · Hillsborough, NJNPI 1417999186

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 25.4% of the total. Reporting peaked in 2022 at $1,436 and has fallen 66.8% since, to $476 in 2025.

$4,147in general payments, 2019–2025

Across 212 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$1K
Sanofi$688
AstraZeneca$669
Optinose US, Inc.$253
Teva Pharmaceuticals USA, Inc.$234
Regeneron Healthcare Solutions, Inc.$228
plus $1K from 16 others

What the payments were for

Food & beverage$3,86893%
Education$2797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	67	$1,055
Sanofi	34	$688
AstraZeneca	34	$669
Optinose US, Inc.	3	$253
Teva Pharmaceuticals USA, Inc.	8	$234
Regeneron Healthcare Solutions, Inc.	10	$228
Sanofi-aventis U.S. LLC	2	$180
Amgen	9	$145
Kaleo, Inc.	7	$102
ARS Pharmaceuticals Operations, Inc.	5	$82
AbbVie	6	$79
Boehringer Ingelheim	5	$73
Takeda Pharmaceuticals U.S.A., Inc.	4	$58
Genentech USA, Inc.	3	$47
Incyte Corporation	3	$44
Octapharma USA, Inc.	1	$42
LEO Pharma Inc.	3	$42
Novartis	2	$35
Aytu Biopharma, Inc.	2	$32
Aimmune Therapeutics, Inc.	2	$26
Mylan Specialty L.p.	1	$21
Merck	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,147 in reported general payments places this provider in the 85th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey →

Other medical in Hillsborough

Shannon WelnerVerona$176K
Christinna DelgenioColts Neck$114K
Anita FoxVerona$17K
Therese CasasKinnelon$16K
Joseph CollettiLinwood$16K
Melissa MiaoKearny$14K
Gabriela Plesek-AndiaVerona$13K
Stephanie PhillipsMarlton$12K
Sean AdairCape May Court House$12K
Shane CourtneyLinwood$11K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →